Prosetin

DB18649InvestigationalSmall molecule

Prosetin is an orally administered blocker of MAP4K under investigation for the treatment of amyotrophic lateral sclerosis.

Code names
PRO-101

Resolves to

Compound
UNIIWJP32276AY

What you can answer from here — as of April 23, 2025

1Clinical trialPhase, status and sponsor resolved per trial
Sign in
1+ReferenceStructured and connected to the statements they support
Sign in

Which companies are running trials of Prosetin, in which indications and phases, and which of those programs are still active?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In